ArticleWorld journal of gastrointestinal oncology2025
Survival prognosis in advanced HER-2 negative gastric cancer treated with immunochemotherapy: A novel model.
Article in World journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Deciphering the potential of the C-reactive protein-albumin-lymphocyte index as a prognostic biomarker in malignancy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Development and validation of a prognostic nomogram for predicting the progression risk of HCC after lenvatinib therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis.World journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer is one of the most common malignant tumors of the digestive system globally, with a generally poor prognosis for patients with advanced disease. In recent years, immune checkpoint inhibitors have made significant advancements in gastric cancer treatment, with some HER-2 negative advanced gastric cancer patients benefiting from the combination of immunotherapy and chemotherapy. However, significant biological heterogeneity exists among patients, resulting in a lack of effective tools to predict the benefits of immunotherapy and survival outcomes. Therefore, there is an urgent need to develop a scientific and precise survival prediction model to provide robust support for personalized treatment decisions.
aimTo develop and validate a novel survival prediction model for assessing the survival risk of advanced HER-2 negative gastric cancer patients receiving immunotherapy combined with chemotherapy, thereby enhancing the accuracy of prognostic evaluation and its clinical guidance value.
methodsThis retrospective study included 200 advanced HER-2 negative gastric cancer patients who received programmed cell death protein 1 inhibitors combined with chemotherapy. Independent prognostic factors for progression-free survival (PFS) and overall survival (OS) were identified using multivariable Cox regression analysis, and a nomogram model was constructed based on these factors. The variables included in the regression analysis were selected based on their clinical relevance, routine application in gastric cancer evaluation, and availability within our dataset. The model's discrimination and calibration were assessed using the concordance index (C-index), the area under the receiver operating characteristic curve (AUC), and calibration plots.
resultsAmong the 200 advanced HER-2 negative gastric cancer patients, multivariable Cox regression analysis identified programmed death-ligand 1 expression level, microsatellite status, tumor-node-metastasis stage, tumor differentiation, neutrophil-to-lymphocyte ratio, and C-reactive protein-albumin-lymphocyte index as independent prognostic factors for PFS and OS (all
conclusionThe nomogram model developed in this study effectively predicts the survival outcomes of advanced HER-2 negative gastric cancer patients receiving immunotherapy combined with chemotherapy, demonstrating good discrimination and consistency, and providing robust support for personalized clinical treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.